Contrast-Enhanced MRI Improves Mesorectal Nodal Staging Accuracy in Rectal Cancer

Refining Preoperative Staging in Rectal Cancer

Colorectal cancer remains the second leading cause of oncologic mortality in the United States, and patient survival is heavily dictated by the accuracy of staging at the time of initial diagnosis [1, 2]. For clinicians managing rectal cancer, the decision to initiate neoadjuvant chemoradiotherapy or pursue organ-preservation strategies depends on the precise identification of local tumor spread and mesorectal lymph node involvement [3, 4]. While multiparametric MRI is the established standard for preoperative evaluation, distinguishing metastatic nodes from reactive ones remains a significant clinical challenge, as standard contrast-enhanced MRI demonstrates a sensitivity of 73% and a specificity of 71% [5]. To improve diagnostic clarity, researchers have turned to dynamic contrast-enhanced sequences (an imaging technique that tracks the uptake and washout of contrast over time to assess tissue perfusion) to exploit the physiological differences in tumor angiogenesis [6, 7]. This study evaluates whether specific quantitative parameters from these functional sequences can provide more reliable nodal staging than current morphological consensus criteria.

Evaluating the Avocado Sign in Clinical Practice

Accurate nodal staging is the pivot point for determining whether a patient requires aggressive neoadjuvant therapy or can safely proceed to surgery. To assess the diagnostic utility of the Avocado Sign, researchers conducted a retrospective single-centre study involving 120 consecutive patients with histopathologically confirmed rectal cancer. This cohort, which underwent 3-T pelvic MRI between January 2020 and May 2025, consisted of 89 men and 31 women with a median age of 65 years (interquartile range 58 to 73). The study compared the diagnostic performance of the Avocado Sign, a specific feature identified on contrast-enhanced MRI, against established T2-weighted morphological criteria for predicting mesorectal lymph node involvement. By utilizing high-field 3-T imaging, which provides superior signal-to-noise ratios and spatial resolution, the researchers sought to determine if this specific enhancement pattern could provide more reliable staging than traditional size or shape-based assessments.

The methodology involved two blinded abdominal radiologists who independently evaluated the imaging data in separate sessions to ensure objective results. In the first session, the radiologists assessed the Avocado Sign on fat-suppressed contrast-enhanced T1-weighted images (a sequence that highlights tissue vascularity and contrast uptake by neutralizing the bright signal typically produced by fat). In a separate session, the same radiologists evaluated T2-weighted morphological features for all mesorectal lymph nodes, which is the current standard for assessing nodal architecture and borders. Mesorectal nodal metastases were histopathologically confirmed in 56 patients (46.7%), providing a rigorous reference standard to measure the accuracy of the Avocado Sign against conventional T2-weighted parameters.

Comparison Against Established Morphological Standards

The researchers utilized total mesorectal excision histopathology (the surgical removal and microscopic examination of the rectum and surrounding fatty tissue) as the definitive reference standard for nodal status. Within the study population, mesorectal nodal metastases were confirmed histopathologically in 56 patients (46.7%), providing a rigorous baseline for evaluating imaging accuracy. The performance of the contrast-enhanced Avocado Sign was measured against several established benchmarks, including the European Society of Gastrointestinal and Abdominal Radiology (ESGAR) consensus criteria, which represent the current standardized guidelines for rectal cancer staging. The study also compared the sign against various literature-derived criteria and a cross-validated cohort-optimised T2 parameter combination (a statistical model that identifies the most predictive T2-weighted features within a specific group and validates them for consistency).

The Avocado Sign demonstrated a high level of diagnostic accuracy, achieving an area under the receiver operating characteristic curve (AUC) of 0.91 (95% confidence interval [CI]: 0.86 to 0.96). This feature yielded a sensitivity of 94.6% (53 of 56 nodes) and a specificity of 87.5% (56 of 64 nodes). In comparison, the ESGAR consensus criteria showed significantly lower diagnostic performance with an AUC of 0.72 (95% CI: 0.64 to 0.81; p < 0.001). The Avocado Sign also exceeded the accuracy of the cohort-optimised T2 parameter combination, which reached an apparent AUC of 0.81 and a cross-validated AUC of 0.79 (p = 0.02). All other literature-derived T2 criteria demonstrated inferior performance, with AUC values ranging from 0.58 to 0.78. These findings indicate that the contrast-enhanced Avocado Sign provides superior discrimination of mesorectal nodal status compared with comprehensive T2-weighted MRI criteria, supporting the routine inclusion of fat-suppressed contrast-enhanced T1-weighted sequences in staging protocols.

Superior Diagnostic Metrics for Nodal Involvement

Quantifying the diagnostic utility of the Avocado Sign reveals a substantial improvement over traditional morphological assessments. The Avocado Sign achieved an AUC of 0.91 (95% confidence interval [CI]: 0.86 to 0.96), a statistical measure where 1.0 represents a perfect test and 0.5 represents chance. In terms of clinical reliability, this imaging feature demonstrated a sensitivity of 94.6% (53 of 56 nodes) and a specificity of 87.5% (56 of 64 nodes). These metrics suggest that the sign is highly effective at both identifying positive nodal involvement and correctly ruling out disease in negative nodes, which is critical for avoiding both undertreatment and the morbidity associated with unnecessary neoadjuvant therapy.

When compared directly to established staging methods, the contrast-enhanced feature showed statistically significant advantages. The Avocado Sign showed higher diagnostic performance than the European Society of Gastrointestinal and Abdominal Radiology (ESGAR) consensus criteria, which yielded an AUC of 0.72 (95% CI: 0.64 to 0.81; p < 0.001). Furthermore, the sign demonstrated superior accuracy over the cohort-optimised T2 parameter combination, which reached an apparent AUC of 0.81 and a cross-validated AUC of 0.79 (p = 0.02). This comparison highlights that even when T2-weighted parameters are statistically optimized for a specific patient group, they do not reach the diagnostic precision of the contrast-enhanced T1-weighted Avocado Sign.

The consistency of these findings is further supported by the evaluation of other existing standards. All literature-derived T2 criteria demonstrated lower performance with AUC values ranging from 0.58 to 0.78, failing to match the 0.91 AUC of the Avocado Sign. For the practicing clinician, these data points underscore the limitations of relying solely on morphological T2-weighted imaging for nodal staging. The high sensitivity and specificity of the Avocado Sign provide a more robust basis for determining which patients require neoadjuvant therapy and which may be candidates for organ-preservation strategies, potentially refining the surgical and oncological management of rectal cancer.

Implications for Neoadjuvant Treatment Selection

The ability to accurately identify mesorectal nodal involvement is a cornerstone of rectal cancer management, as it dictates the necessity of neoadjuvant chemoradiotherapy. In this study of 120 patients, the contrast-enhanced Avocado Sign provided superior discrimination of mesorectal nodal status compared with comprehensive T2-weighted MRI criteria, which have historically served as the imaging standard. By achieving an area under the receiver operating characteristic curve (AUC) of 0.91 (95% confidence interval [CI]: 0.86 to 0.96), this feature allows clinicians to more reliably differentiate between metastatic and benign nodes than the European Society of Gastrointestinal and Abdominal Radiology (ESGAR) consensus criteria, which yielded a significantly lower AUC of 0.72 (p < 0.001). This improved diagnostic precision is essential for refining patient selection for neoadjuvant therapy, ensuring that those with confirmed nodal disease receive intensive treatment while those without it are spared unnecessary toxicity.

Beyond initial staging, these findings have direct implications for organ-preservation strategies, such as "watch and wait" protocols, where the presence of residual or occult nodal disease can lead to local recurrence. The high sensitivity of 94.6% (53 of 56 nodes) and specificity of 87.5% (56 of 64 nodes) associated with the Avocado Sign suggest that it can more effectively guide the selection of candidates for non-operative management. Consequently, the findings support routine inclusion of fat-suppressed contrast-enhanced T1-weighted sequences in rectal cancer staging protocols to augment standard T2-weighted imaging. Incorporating these sequences into clinical practice provides a more robust evidence base for individualized treatment planning, potentially reducing the rates of both undertreatment in high-risk patients and overtreatment in those with localized disease.

References

1. Levin B, Lieberman DA, McFarland BH, et al. Screening and Surveillance for the Early Detection of Colorectal Cancer and Adenomatous Polyps, 2008: A Joint Guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. CA A Cancer Journal for Clinicians. 2008. doi:10.3322/ca.2007.0018

2. Smith RA, Andrews K, Brooks D, et al. Cancer screening in the United States, 2019: A review of current American Cancer Society guidelines and current issues in cancer screening. CA A Cancer Journal for Clinicians. 2019. doi:10.3322/caac.21557

3. Bauer F. The Importance of Preoperative Staging of Rectal Cancer Using Multiparametric MRI. A Systematic Review. Chirurgia. 2016. doi:10.21614/chirurgia.111.5.379

4. Benson AB, Venook AP, Al-Hawary MM, et al. Rectal Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network. 2022. doi:10.6004/jnccn.2022.0051

5. Yazdi SNM, Moradi SA, Rasoulighasemlouei SS, Parouei F, Hashemi MG. Quantitative Dynamic Contrast-Enhanced Magnetic Resonance Imaging and Positron Emission Tomography (PET) for Distinguishing Metastatic Lymph Nodes from Nonmetastatic Among Patients with Rectal Cancer: A Systematic Review and Meta-Analysis.. World journal of nuclear medicine. 2025. doi:10.1055/s-0044-1788794

6. Meyer HJ, Wienke A, Surov A. Correlation Between K_trans and Microvessel Density in Different Tumors: A Meta-analysis.. Anticancer research. 2018. doi:10.21873/anticanres.12543

7. Ferrara N. Vascular Endothelial Growth Factor: Basic Science and Clinical Progress. Endocrine Reviews. 2004. doi:10.1210/er.2003-0027